This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.

Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)

Search by Country
A1M Pharma has developed the exogenous production of functional Alfa-1-Microglobulin to lab scale and has been investigating the functional uses of the protein in various models. The principal effects of A1M administration centre on the restoration of renal function following acute kidney injuries and the provision of a protective effect in situations where release of reactive oxygen species ROS e.g. heme can threaten end organs such as the kidneys with damage through oxidative stress. Therapeutic effects in animal models show positive effects on blood pressure, filtration capacity and proteinuria.
North Rhine-Westphalia
A2M (academia to market) Pharmaceuticals is a spin-off of Schwarz Pharma that is developing the Schwarz CNS portfolio following the merger with UCB. A2M Pharma project portfolio focusses on the therapeutic areas central nervous system and pain. The company develops these projects until clinical proof of concept (POC, clinical phase IIa) which will then be outlicensed or partnered to pharma companies.
Ann Arbor
Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in US clinical trials in the treatment of dilated cardiomyopathy (DCM).
Abacus Diagnostica Oy is a Finnish molecular diagnostics company specialized in rapid DNA testing utilizing its proprietary GenomEra?-technology. Company's mission is to provide innovative and simple-to-use solutions to enable routine use of DNA based testing without compromising the quality of results and move the molecular diagnostic to the next level of easiness.
New Jersey
Abeille Pharmaceuticals, Inc. operates as a pharmaceutical product development company. Company?s initial focus is on developing products in oncology supportive care and diabetes and related metabolic disorders, based on technologies such as transdermal delivery and oral controlled-release systems.
Abeome Corporation is a privately-held biotechnology company that discovers therapeutic and diagnostic monoclonal antibodies (mAbs) using their proprietary technology. Company makes custom mAbs under both fee-for-service and co-development agreements to serve academic and corporate partners around the world.
Abera Bioscience AB (Abera) is a Swedish biotech company that focuses on novel vaccines and vaccine development technologies. Abera currently has a portfolio of vaccine candidates in preclinical phase based on its proprietary technologies, Bera-D, that allows high-density display of multiple antigens on the surface of attenuated Salmonella (and other Gram-negative bacteria) or derived Outer Membrane Vesicles (OMVs), Bera-V. These can be used to produce vaccines, efficiently presenting the antigens to the immune system of the patient. In addition, they developed the Bera-S platform for efficient secretory expression of antigens allowing the generation of potent multivalent subunit vaccines.
Los Altos
AbGenomics International Inc., incorporated in Delaware with principal office in San Francisco Bay Area, is a biopharmaceutical company with its R&D foundation established since June 2000. AbG is a clinical stage company integrated globally and virtually to develop antibody therapeutics and companion diagnostics for the treatment of cancer and immune related inflammatory diseases.
Abgent develops primary antibodies & provides first-in-class custom peptide synthesis & antibody development. The antibodies are widely used for autophagy, apoptosis, stem cells, phosphorylation, cell function & gene regulation research. Synthesis of difficult peptides, including long peptides, is a core competency. High-quality, rapid turnaround & personal support is guaranteed.

The purpose of GOAL is to provide one or more validated antibodies for every human protein. This antibody sensing library will accelerate research in the life sciences.
San Diego
Abide Therapeutics develop innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Abide has created a proprietary platform, that specifically targets serine hydrolases with selective small molecules.
Bellaterra - Barcelona - Catalonia
Ability Pharmaceuticals is a clinical stage biopharmaceutical company located in Barcelona, Catalonia, Spain.

The company has developed a proprietary new drug class called Lipid Analogue Therapeutics. Ability Pharmaceuticals has two drugs candidates in development in several cancer types:

? ABTL0812 which starts Phase I/Ib clinical trials (First in Humans) in October 2013: Preclinical data has shown efficacy in lung cancer and pancreatic cancer.

? ABTL1014 is in preclinical development and targets hematologic malignancies.

The company develops the new drug candidates up through clinical proof of concept, and will then out-license them to biopharmaceutical companies for further development.

The company participates in this convention to raise funds for the phase II clinical program of ABTL0812, to fund the preclinical development of ABTL1014 and to fully exploit its patented drug discovery platform to generate new anti-cancer drug candidates.
Ablitech, Inc. is a biotechnology company dedicated to the development and commercializing of platform technologies that heal and protect the human body. Ablitech's Versadel therapy is a platform technology for treatment of a variety of diseases such as cancer, HIV, and other diseases resulting from genetic abnormalities. Initial development of this technology is focused on a pancreatic and bladder cancer therapy, but behold the possibilities.